Cassie Jung Biography and Net Worth

Cassie Jung joined Aquestive in 2004 and since then, has held leadership positions across various areas of the business including Quality Assurance, Alliance Management, Clinical Operations, and Portfolio Management. Ms. Jung was instrumental in the execution of Aquestive’s internal CNS development pipeline and in 2019, was appointed Vice President Operations, responsible for all facets of the company’s manufacturing operations.

Ms. Jung is currently the Chief Operating Officer and oversees several key functions across the company, including manufacturing operations, product management, and corporate communications. Ms. Jung received her B.S. in Management from Purdue University.

What is Cassie Jung's net worth?: The estimated net worth of Cassie Jung is at least $1.14 million as of March 10th, 2026. Ms. Jung owns 274,980 shares of Aquestive Therapeutics stock worth more than $1,135,667 as of April 6th. This net worth evaluation does not reflect any other investments that Ms. Jung may own. Learn More about Cassie Jung's net worth.
How do I contact Cassie Jung?: The corporate mailing address for Ms. Jung and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Cassie Jung's contact information.
Has Cassie Jung been buying or selling shares of Aquestive Therapeutics?: Cassie Jung has not been actively trading shares of Aquestive Therapeutics during the last quarter. Most recently, Cassie Jung sold 45,791 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a transaction totalling $190,948.47. Following the completion of the sale, the chief operating officer now directly owns 274,980 shares of the company's stock, valued at $1,146,666.60. Learn More on Cassie Jung's trading history.
Who are Aquestive Therapeutics' active insiders?: Aquestive Therapeutics' insider roster includes Daniel Barber (CEO), Peter Boyd (Insider), Lori Braender (Insider), Melina Cioffi (SVP), Ernest Jr (CFO), Cassie Jung (COO), Sherry Korczynski (Insider), Carl Kraus (Insider), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.
Are insiders buying or selling shares of Aquestive Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 672,460 shares worth more than $3,342,230.34. The most recent insider tranaction occured on March, 10th when insider Peter E Boyd sold 29,814 shares worth more than $124,324.38. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.
Information on this page was last updated on 3/10/2026.

Cassie Jung Insider Trading History at Aquestive Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2026	Sell	45,791	$4.17	$190,948.47	274,980
10/15/2025	Sell	67,575	$7.01	$473,700.75	240,771
9/4/2025	Sell	62,180	$5.00	$310,900.00	283,346
11/26/2024	Sell	44	$4.87	$214.28	233,066

Cassie Jung Buying and Selling Activity at Aquestive Therapeutics

Aquestive Therapeutics Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Today's Range

Now: $4.11

$4.10

$4.16

50 Day Range

MA: $3.96

$2.95

$4.37

2 Week Range

Now: $4.11

$2.12

$7.55

Volume

466,996 shs

Average Volume

4,558,474 shs

Market Capitalization

$500.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54